Sapience Therapeutics
Company Details
Status: Private
Employees: 11-50
Location:
Tarrytown, New York, United States
Type:
sample
Technology:
sample
sample
sample
About: At Sapience, we think boldly about the possibilities for treating cancer. We aim to discover and develop peptide therapeutics to address oncogenic and immunogenic dysregulation that drive cancer. Our pipeline of SPEARs™ (Stabilized Peptides Engineered Against Regulation) disrupt intracellular protein-protein interactions, enabling targeting of transcription factors which have traditionally been considered undruggable. We are advancing our lead programs, ST316, a first-in-class antagonist of β-catenin, and lucicebtide (formerly known as ST101), a first-in-class antagonist of C/EBPβ, through Phase 2 clinical trials. Please engage with us on this platform to learn more!
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Sapience Therapeutics | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.